Amlodipine Drug Classification
Amlodipine is a dihydropyridine calcium channel blocker.
Drug Class Details
Amlodipine belongs to the dihydropyridine subclass of calcium channel blockers (CCBs), which is one of three chemically distinct subclasses of calcium antagonists 1, 2, 3, 2, 4.
The Three Subclasses of Calcium Channel Blockers:
- Dihydropyridines (e.g., amlodipine, nifedipine, felodipine) 1, 5, 2
- Benzothiazepines (e.g., diltiazem) 1, 2
- Phenylalkylamines/Phenylethylamines (e.g., verapamil) 1, 2
Key Pharmacological Characteristics
Amlodipine has high vascular selectivity, producing marked peripheral arterial vasodilation with minimal effects on myocardial contractility or cardiac conduction 1, 2, 4. This distinguishes it from non-dihydropyridine CCBs (diltiazem and verapamil), which have greater effects on the myocardium and can cause negative inotropic and chronotropic effects 3.
Important Clinical Distinctions:
The 2023 AACE guidelines explicitly corrected a common error, clarifying that amlodipine is a dihydropyridine, NOT a non-dihydropyridine 6. This correction was necessary because amlodipine and nifedipine were incorrectly labeled as non-dihydropyridines in earlier versions of their algorithm.
Mechanism of Action:
Amlodipine inhibits calcium influx through L-type calcium channels located in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance 3, 7. It is a potent peripheral and coronary vasodilator with high selectivity for vascular smooth muscle 7.
Clinical Implications of Drug Class
The dihydropyridine classification has important therapeutic implications:
- Preferred in heart failure with reduced ejection fraction (HFrEF): Unlike non-dihydropyridine CCBs (which are contraindicated), dihydropyridines like amlodipine can be used safely in HFrEF patients 8
- No significant effects on heart rate or AV conduction: Making it suitable for patients without contraindications to these effects 1, 3
- Potent vasodilatory effects: Producing the most marked peripheral arterial vasodilation among CCB subclasses 1, 2, 4
Common Pitfall:
Do not confuse amlodipine with non-dihydropyridine CCBs. This distinction matters clinically because non-dihydropyridines (diltiazem, verapamil) have myocardial depressant effects and are contraindicated in HFrEF 8, while amlodipine can be used safely in these patients.